Regeneron/Bayers VEGF Trap eye shows efficacy in AMD « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Regeneron/Bayers VEGF Trap eye shows efficacy in AMD

Posted on September 29, 2008 by crimsoncanary

Data presented at the Retina Society meeting show Bayer/Regeneron’s VEGF Trap-Eye can improve visual acuity and biologic parameters related to the formation of new blood vessels in the treatment of age-related macular degeneration (AMD).

Filed under: Uncategorized | Tagged: bayer, regeneron, VEGF-Trap, VEGFTrap

« Astex and Cancer Research UK collaborate on PKB inhibitor ImClone initiate Phase II trial of IMC-1121B in ovarian cancer »